References
- Tumbarello M, Trecarichi EM, Fiori B, et al. Multidrug-resistant Proteus mirabilis bloodstream infections: risk factors and outcomes. Antimicrob Agents Chemother. 2012;56:3224–3231.
- Endimiani A, Luzzaro F, Brigante G, et al. Proteus mirabilis bloodstream infections: risk factors and treatment outcome related to the expression of extended-spectrum β-lactamases. Antimicrob Agents Chemother. 2005;49:2598–2605.
- O‘Hara CM, Brenner FW, Miller JM. Classification, identification, and clinical significance of Proteus, Providencia, and Morganella. Clin Microbiol Rev. 2000;13:534–546.
- Stürenburg E, Mack D. Extended-spectrum beta-lactamases: implications for the clinical microbiology laboratory, therapy, and infection control. J Infect. 2003;47:273–295.
- Tibbetts R, Frye JG, Marschall J, et al. Detection of KPC-2 in a Clinical Isolate of Proteus mirabilis and First Reported Description of Carbapenemase Resistance Caused by a KPC beta-Lactamase in P. mirabilis. J Clin Microbiol. 2008;46:3080–3083.
- Cohen-Nahum K, Saidel-Odes L, Riesenberg K, et al. Urinary Tract Infections caused by multi-drug resistant Proteus mirabilis: risk factors and clinical outcomes. Infection. 2010;38:41–46.
- Schwaber MJ, Carmeli Y. Mortality and delay in effective therapy associated with extended-spectrum beta-lactamase-production in Enterobactereaceae bacteremia: a systematic review and meta-analysis. J Antimicrob Chemother. 2007;60:913–920.
- Kurihara Y, Hitomi S, Oishi T, et al. Characteristics of bacteremia caused by extended-spectrum beta-lactamase-producing Proteus mirabilis. J Infect Chemother. 2013;19:799–805.
- Bauer AW, Kirby WM, Sherris JC, Turck M. Antibiotic susceptibility testing by a standardized single disk method. Am J Clin Pathol. 1966;45:493–496.
- Webster DP, Young BC, Morton R, et al. Impact of a clonal outbreak of extended-spectrum β-lactamase-producing Klebsiella pneumoniae in the development and evolution of bloodstream infections by K. pneumoniae and Escherichia coli: an 11 year experience in Oxfordshire, UK. J Antimicrob Chemother. 2011;66:2126–2135.
- Nasa P, Juneja D, Singh O, et al. An observational study on bloodstream extended-spectrum beta-lactamase infection in critical care unit: incidence, risk factors and its impact on outcome. Eur J Intern Med. 2012;23:192–195.
- Serefhanoglu K, Turan H, Timurkaynak FE, Arslan H. Bloodstream infections caused by ESBL-producing E. coli and K. pneumoniae: risk factors for multidrug-resistance. Braz J Infect Dis. 2009;13:403–407.
- Peralta G, Lamelo M, Alvarez-García P, et al. SEMI- BLEE STUDY GROUP. Impact of empirical treatment in extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella spp. bacteremia. A multicentric cohort study. BMC Infect Dis. 2012;12:245.
- Orsini J, Mainardi C, Muzylo E, et al. Microbiological profile of organisms causing bloodstream infection in critically ill patients. J Clin Med Res. 2012;4:371–377.
- Matsumura Y, Yamamoto M, Matsushima A, et al. Cefotaxime for the detection of extended-spectrum β-lactamase or plasmid-mediated AmpC β-lactamase and clinical characteristics of cefotaxime-non-susceptible Escherichia coli and Klebsiella pneumoniae bacteraemia. Eur J Clin Microbiol Infect Dis. 2012;31:1931–1939.
- Chen C-Y, Chen Y-H, Lu P-L, et al. Proteus mirabilis urinary tract infection and bacteremia: risk factors, clinical presentation, and outcomes. J Microbiol Immunol Infect. 2012;45:228–236.
- Lewis J, Fekety FR. Jr. Proteus bacteremia. Johns Hopkins Med J. 1969;124:151–156.
- Adler JL, Burke JP, Martin DF, Finland M. Proteus infections in a general hospital. II. Some clinical and epidemiological characteristics. With an analysis of 71 cases of proteus bacteremia. Ann Intern Med. 1971;75:531–536.
- Follmer C. Ureases as a target for the treatment of gastric and urinary infections. J Clin Pathol. 2010;63:424–430.